ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,631.22
0.28%
US Tech 100
19,884.80
0.46%
Dow Jones
40,211.72
0.53%
Brent Oil
84.005
-0.40%
Bitcoin
64,115.63
-1.13%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Prime Medicine Inc (PRME) Quote

Prime Medicine Inc

Prime Medicine Inc (PRME)

Prim SA
Prim SA
Prim SA
Prim SA
Prime Drink Group Corp
5.78
0.07
(1.23%)
Closed July 16 4:00PM
Delayed by 15 minutes
5.73
-0.05
(-0.87%)
After Hours: 7:51PM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
5.73
Bid
5.53
Ask
6.25
Volume
793,147
5.54 Day's Range 5.86
4.11 52 Week Range 15.47
Market Cap
685.376M
Previous Close
5.71
Open
5.73
Last Trade
21
@
5.9
Last Trade Time
Financial Volume
$ 4,498,976
VWAP
5.6723
Average Volume (3m)
954,128
Shares Outstanding
120,030,813
Dividend Yield
-
PE Ratio
-3.50
Earnings Per Share (EPS)
-1.65
Revenue
-
Net Profit
-198.13M

About Prime Medicine Inc

Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome a... Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.primemedicine.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Prime Medicine Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker PRME. The last closing price for Prime Medicine was $5.71. Over the last year, Prime Medicine shares have traded in a share price range of $ 4.11 to $ 15.47.

Prime Medicine currently has 120,030,813 shares outstanding. The market capitalization of Prime Medicine is $685.38 million. Prime Medicine has a price to earnings ratio (PE ratio) of -3.50.

PRME Latest News

More News

Form 4 - Statement of changes in beneficial ownership of securities

June 14 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

June 14 2024
Edgar (US Regulatory)

Form 8-K - Current report

June 12 2024
Edgar (US Regulatory)

Prime Medicine to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic...

May 30 2024
GlobeNewswire Inc.

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

May 21 2024
Edgar (US Regulatory)

Form 8-K - Current report

May 21 2024
Edgar (US Regulatory)

Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic...

May 13 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 10 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.346.307977736555.396.265.256748945.7255999CS
4-1.29-18.37606837617.027.0734.9910156595.59231711CS
121.0422.17484008534.698.274.119541286.08704242CS
26-1.8-23.90438247017.539.774.118130096.5301082CS
52-9.26-61.774516344214.9915.474.116335937.53534547CS
156-13.24-69.794412229818.9721.73014.114911899.62052624CS
260-13.24-69.794412229818.9721.73014.114911899.62052624CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AMIXAutonomix Medical Inc
$ 1.3701
(121.70%)
154.81M
SHOTWSafety Shot Inc
$ 0.41
(115.79%)
7.56k
DATSDatChat Inc
$ 1.89
(81.73%)
54.75M
CYNCYNGN Inc
$ 9.18
(53.77%)
17.79M
SCNIScinai Immunotherapeutics Ltd
$ 5.80
(42.86%)
29.37M
ASLNASLAN Pharmaceuticals Ltd
$ 1.36
(-46.67%)
1.16M
KZIAKazia Therapeutics Ltd
$ 0.5593
(-37.56%)
15.34M
LCFYLocafy Ltd
$ 3.5597
(-36.32%)
584.38k
NAASNaaS Technology Inc
$ 2.82
(-33.02%)
1.94M
ZENVZenvia Inc
$ 1.67
(-26.75%)
658.26k
FFIEFaraday Future Intelligent Electric Inc
$ 0.5152
(22.09%)
217.92M
NVDANVIDIA Corporation
$ 128.44
(-0.62%)
208.32M
SQQQProShares UltraPro Short QQQ
$ 7.46
(-0.67%)
155.14M
AMIXAutonomix Medical Inc
$ 1.3701
(121.70%)
154.81M
TSLATesla Inc
$ 252.64
(1.78%)
147.31M

PRME Discussion

View Posts
Monksdream Monksdream 2 weeks ago
PRME under $10:
👍️0
Monksdream Monksdream 1 month ago
Great post
Friday Cathie Wood bought more shares for her flagship Ark Fund (ARKK)
I think she has been buying on the decline
She isn’t particularly interested in how well or how lousy the management controls costs it’s the potential she believes exists
There are about a dozen, if not more, listed gene editing companies
Not all will make it before they run out of money and have to raise more operating capital
Notice the $2 to $4 bounces on the way to lower lows
👍️0
Monksdream Monksdream 2 months ago
PRME under $10
👍️0
jondoeuk jondoeuk 2 months ago
PRME vs Tome vs Tessera vs NTLA vs CRSP vs...!

They fact this article needs to be written could mean a legal battle is coming https://www.nature.com/articles/s41587-024-02208-0
👍️0
NY1972 NY1972 3 months ago
This $500M company burns $200M a year. These PhDs have been spoiled by Wall St. when money was cheap. Who wants to be their sugar daddy?
👍️0
jondoeuk jondoeuk 3 months ago
I'm sure in the (near) future they will (functionally) cure (rare) diseases, but not before they dilute a whole bunch more.
👍️0
jondoeuk jondoeuk 5 months ago
The CEO has been contently telling investors how easy it would be to bring in funding through partnerships and how difficult capital markets are. Yet they did a secondary. He needs to go. Also, I don't think their IP is gatekeeping others.
👍️0

Your Recent History

NASDAQ
PRME
Prime Medicine
AMEX
ICF
iShares Cohen and Steers...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved